Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract contains no research findings; it outlines website features and access options for the JAMA network's publications.

This study found that aminoguanidine induces VEGF mRNA expression in stored hair follicle micrografts and outer root sheath cells, suggesting potential for enhancing growth factor production during storage.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

In this study, researchers found that applying mometasone furoate 0.1% cream combined with adapalene 0.1% gel resulted in significantly greater hair regrowth over 12 weeks compared to mometasone furoate cream alone in patients with alopecia areata.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

This study found that hair root sheaths can be accurately typed for erythrocyte acid phosphatase, adenylate kinase, and adenosine deaminase, consistent with blood typing results from the same donors.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This preclinical study found that a machine-learning-driven strategy for fabricating microneedles with optimal hardness and rapid dissolution significantly promoted hair regrowth in androgenetic alopecia mice by activating the Wnt/β-catenin pathway, surpassing the effects of minoxidil.

In this study, researchers identified a recurrent MBTPS2 splice-site variant as a mutational hotspot in IFAP syndrome across diverse families, with phenotype severity suggesting the influence of additional modifiers.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

This study demonstrates that machine learning-assisted fabrication of PRP-incorporated microneedles effectively promotes hair regrowth in AGA mice, outperforming minoxidil and mitigating biosafety risks associated with synthetic materials.

This study found that combining a 308-nm excimer lamp with minoxidil led to significant hair regrowth in alopecia areata patients, with side effects like hyperpigmentation being tolerable.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This article discusses the potential benefits of GcMAF and oral MAF, developed by "Saisei Mirai", for cancer and other conditions, but reports no new clinical results.

In this study, researchers reported that adenosine stimulated hair shaft elongation in cultured human hair follicles by promoting proliferation and prolonging the anagen phase, suggesting the A2B adenosine receptor in outer root sheath keratinocytes as a promising target for treating hair growth disorders like alopecia.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study found that scalp microinfusion with dutasteride using microneedling and tattoo devices appears safe and shows promise as a treatment for male androgenetic alopecia, resulting in stabilization or improvement in 96.7% of patients, although further controlled studies are needed.

This study found that using a wearable low-level light therapy device for photodynamic therapy significantly reduced actinic keratosis lesions and improved quality of life in patients with AK of the scalp.

This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.

This letter to the editor comments on the association between androgenetic alopecia and increased scalp hardness, exploring the possible role of phosphodiesterase inhibitors but provides no new clinical results.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.